Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non-Current Liabilities (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Other Non-Current Liabilities readings, the most recent being $269000.0 for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 14.47% to $269000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $269000.0, a 14.47% increase, with the full-year FY2025 number at $260000.0, up 12.55% from a year prior.
  • Other Non-Current Liabilities hit $269000.0 in Q4 2025 for Enanta Pharmaceuticals, up from $260000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.5 million in Q3 2021 to a low of $87000.0 in Q2 2022.
  • Median Other Non-Current Liabilities over the past 5 years was $326500.0 (2021), compared with a mean of $513500.0.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 389.66% in 2023 and later tumbled 83.77% in 2024.
  • Enanta Pharmaceuticals' Other Non-Current Liabilities stood at $336000.0 in 2021, then grew by 23.21% to $414000.0 in 2022, then skyrocketed by 56.76% to $649000.0 in 2023, then tumbled by 63.79% to $235000.0 in 2024, then increased by 14.47% to $269000.0 in 2025.
  • The last three reported values for Other Non-Current Liabilities were $269000.0 (Q4 2025), $260000.0 (Q3 2025), and $252000.0 (Q2 2025) per Business Quant data.